To investigate the curative effect of idebenone combined with levodopaand benserazide hydrochlo-ride (LBH) on Parkinson’s disease (PD) and their influences on cerebrospinal fluid (CSF) related inflammatory factors.

Sixty PD patients who were admitted to the Nanyang Central Hospital from May 2014 to May 2019 were enrolled, and they were divide into observation group and control group by random number table method, with 30 cases in each group. The control group was treated with LBH, while observation group was treated with idebenone combined with LBH. The response rate of treatment, change in scores of united Parkinson disease rating scale-III (UPDRS-III), oxidative stress indexes and CSF-related inflammatory factors, and adverse reactions before and after treatment in both groups were observed.

The response rate of treatment in observation group was higher than that in control group (P<0.05). Four weeks and 12 weeks after treatment, UPDRS-III score of observation group was lower than that of control group (P<0.05). After treatment, superoxide dismutase (SOD) level in observation group was higher than that in control group, while levels of 8-hydroxydeoxyguanosine (8-OHdG) and malondialdehyde (MDA) were lower than those in control group (P<0.05). After treatment, interleukin-6 (IL-6), interleukin-1β(IL-1β), tumor necrosis factor-α (TNF-α) and interferon γ(IFN-γ) in CSF of both groups were significantly decreased (P<0.05). Before and after treatment, there was no significant difference in CSF-related inflammatory factors (IL-6, IL-1β, TNF-α, IFN-γ) levels between the two groups (P>0.05). There was no difference in adverse reaction rate between the two groups (P<0.05).

Idebenone combined with LBH in treatment of PD patients can improve response rate of treatment, decrease UPDRS-III score, and enhance antioxidant activity with few adverse reactions and high safety.

Parkinson’s disease; Idebenone; Levodopaand benserazide hydrochlo-ride; Inflammatory factor